By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer released trial data on a new obesity drug, raising concerns about tolerability. Despite a stock drop, the company aims ...

Pfizer's experimental obesity drug, acquired through Metsera, shows promise, reporting up to 12.3% weight loss in a 28-week ...

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The ...

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...